Opioid-induced constipation

Summary

Opioid-induced constipation (MONDO:0100187) is a disease and 59 clinical trials. Top therapeutic interventions include naloxegol, methylnaltrexone, and naldemedine. A subtype of constipation disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 59

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	opioid-induced constipation
Mondo ID	MONDO:0100187
UMLS	C3160897
MedGen	1641995
Is cancer (heuristic)	no

Also known as: OIC

Disease family

This is a subtype of constipation disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › digestive system disorder › intestinal disorder › bowel dysfunction › constipation disorder › opioid-induced constipation

Related subtypes (1): outlet dysfunction constipation

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 59.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE3	19
Not specified	14
PHASE2	13
PHASE4	8
PHASE1/PHASE2	2
PHASE1	2
PHASE2/PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06897917	PHASE4	NOT_YET_RECRUITING	Real World Study of Oxycodone/Naloxone Sustained-Release Tablets (Mimeixin) for Patients With Severe Cancer Pain
NCT00672139	PHASE4	COMPLETED	Safety of Subcutaneous Methylnaltrexone for Opioid-Induced Constipation in Patients With Advanced Illness
NCT00672477	PHASE4	COMPLETED	Study Evaluating Subcutaneous Methylnaltrexone For Treatment Of Opioid-Induced Constipation In Patients With Advanced Illness
NCT00858754	PHASE4	WITHDRAWN	Study Evaluating Safety & Efficacy of Subcutaneous Methylnaltrexone on Opioid-Induced Constipation in Cancer Subjects
NCT01109511	PHASE4	COMPLETED	A Comparison of Oxycodone/Naloxone and Oxycodone After Laparoscopic Hysterectomy
NCT01957046	PHASE4	COMPLETED	A Single-arm, Study to Assess the Effect and Tolerability of Standardised Laxative Therapy (SLT) for the Reversal of Opioid-induced Constipation (OIC).
NCT03060512	PHASE4	COMPLETED	To Evaluate Patient Preference of Movantik and Polyethylene Glycol 3350 for Opioid Induced Constipation
NCT05770960	PHASE4	COMPLETED	Colonic Motor Patterns in Healthy Volunteers
NCT07534995	PHASE3	NOT_YET_RECRUITING	A Prospective, Multicenter, Randomized, Parallel-controlled, Superiority Trial
NCT00399659	PHASE3	TERMINATED	Safety and Efficacy of Tegaserod in Opioid-induced Constipation in Patients With Non-cancer Pain.
NCT00414024	PHASE3	TERMINATED	Safety and Efficacy of Tegaserod in Opioid-induced Constipation in Patients With Non-cancer Pain.
NCT01050595	PHASE3	UNKNOWN	Methylnaltrexone for Treatment of Opiate-Induced Constipation in the Intensive Care Unit
NCT01117051	PHASE3	TERMINATED	Prucalopride Effects on Subjects With Chronic Non-cancer Pain Suffering From Opioid Induced Constipation
NCT01186770	PHASE3	COMPLETED	A Study of Oral Methylnaltrexone (MNTX) for the Treatment of Opioid-Induced Constipation (OIC) in Participants With Chronic, Non-Malignant Pain
NCT01309841	PHASE3	COMPLETED	Assessment of Efficacy and Safety in Patients With Non-cancer-related Pain and Opioid-induced Constipation
NCT01323790	PHASE3	COMPLETED	Assessment of Efficacy and Safety in Patients With Non-cancer-related Pain and Opioid-induced Constipation
NCT01336205	PHASE3	COMPLETED	Assessment of Long-term Safety in Patients With Non-cancer-related Pain and Opioid-induced Constipation
NCT01384292	PHASE3	TERMINATED	Assessment of Efficacy and Safety in Relieving Opioid-induced Constipation in Patients With Cancer-related Pain
NCT01395524	PHASE3	COMPLETED	A 12-week Extension of the Phase III Study (D3820C00004) to Assess the Effect and Safety of NKTR-118 in Patients With Non-cancer-related Pain and Opioid-induced Constipation
NCT01696643	PHASE3	TERMINATED	Safety Study of CB-5945 for the Treatment of Opioid-Induced Constipation
NCT01901302	PHASE3	TERMINATED	Efficacy and Safety Study of CB-5945 for the Treatment of Opioid-Induced Constipation
NCT01901328	PHASE3	TERMINATED	Efficacy and Safety Study of CB-5945 for the Treatment of Opioid-Induced Constipation
NCT01901341	PHASE3	TERMINATED	The Efficacy and Safety Study of CB-5945 for the Treatment of Opioid-Induced Constipation
NCT01965158	PHASE3	COMPLETED	Efficacy and Safety of Naldemedine in the Treatment of Opioid-induced Constipation
NCT01965652	PHASE3	COMPLETED	Long Term Safety of Naldemedine
NCT01993940	PHASE3	COMPLETED	Efficacy and Safety of Naldemedine in Treating Opioid-induced Constipation
NCT02574819	PHASE2/PHASE3	UNKNOWN	Study of Methylnaltrexone in Opioid-Induced Constipation Patients
NCT03687268	PHASE3	UNKNOWN	Naloxone HCl PR Tablets in Patients With Opioid Induced Constipation
NCT05588323	PHASE1/PHASE2	RECRUITING	Safety and Pharmacokinetics Study of Naldemedine in Paediatric Participants Receiving Opioids
NCT00600119	PHASE2	COMPLETED	A Phase 2, Double-Blind, Multiple-Dose Escalation Study to Evaluate NKTR-118 (Oral PEG-Naloxol) in Patients With Opioid-Induced Constipation (OIC)
NCT00640146	PHASE2	COMPLETED	Study of Subcutaneous Methylnaltrexone (MNTX) in the Treatment of Opioid-Induced Constipation During Rehabilitation After Orthopedic Procedures
NCT00984334	PHASE2	COMPLETED	Naloxone SR Capsules in Patients With Opioid Induced Constipation
NCT01040637	PHASE1/PHASE2	COMPLETED	A Multiple Dose Study of TD-1211 in Healthy Volunteers and Patients With Opioid-Induced Constipation
NCT01100151	PHASE2	COMPLETED	ALK37-003: A Study of RDC-1036 (ALKS 37) in Adults With Opioid-induced Constipation (OIC)
NCT01207427	PHASE2	COMPLETED	Evaluation of the Efficacy and Safety of ADL5945 for the Treatment of Opioid-induced Constipation in Adults Taking Opioid Therapy for Chronic Noncancer Pain
NCT01333540	PHASE2	COMPLETED	A Study to Assess the Safety, Tolerability and Clinical Activity of TD-1211 in Patients With Opioid-Induced Constipation
NCT01382797	PHASE2	COMPLETED	ALK37-005: A Study of ALKS 37 (RDC-1036) in Adults With Opioid-induced Constipation (OIC)
NCT01401985	PHASE2	COMPLETED	A Study of TD-1211 in Subjects With Opioid-Induced Constipation (OIC)
NCT01418092	PHASE2	COMPLETED	ALK37-007: Evaluation of Safety and Efficacy of ALKS 37 (RDC-1036) in Adults With Opioid-induced Constipation (OIC)
NCT01443403	PHASE2	COMPLETED	A Study of Naldemedine (S-297995) for the Treatment of Opioid-Induced Constipation in Adults With Non-Malignant Chronic Pain Receiving Opioid Therapy

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
NALOXEGOL	4	29
METHYLNALTREXONE	4	16
NALDEMEDINE	4	7
TEGASEROD	4	6
NALOXONE	4	2
OXYCODONE	4	2
PRUCALOPRIDE	4	2
BISACODYL	4	1
CODEINE PHOSPHATE	4	1
LACTULOSE	4	1
LINACLOTIDE	4	1
LUBIPROSTONE	4	1
MAGNESIUM CITRATE	4	1
MAGNESIUM HYDROXIDE	4	1
POLYETHYLENE GLYCOL 3350	4	1
BEVENOPRAN	3	5
SENNA	3	1
AXELOPRAN	2	4
METHYLSAMIDORPHAN	2	2
DOCUSATE CALCIUM	1	1
CHEMBL4747028	0	1